RSS   Newsletter   Contact   Advertise with us
Post Online Media

Blueprint Medicines appoints Marion Dorsch as CSO

Blueprint MedicinesBlueprint Medicines Corporation announced that Marion Dorsch will be its new chief scientific officer from November 21, 2016.

Dr. Dorsch joins Blueprint Medicines from Agios Pharmaceuticals where she served as Vice President of Biology.

Article continues below

READ MORE Blueprint Medicines names chief business officer

Prior to joining Agios, Dr. Dorsch was the Director of Cancer Biology at Sanofi Oncology.

She served as research project leader for sonidegib (Odomzo), now approved in the U.S. and EU for the treatment of locally advanced basal cell carcinoma, at the Novartis Institutes for Biomedical Research and also worked in Inflammation Discovery at Millennium Pharmaceuticals.

Dr. Dorsch received her Ph.D. in Biology from the Free University of Berlin, Germany and was a postdoctoral fellow at Columbia University in New York.


 LATEST MOVES FROM Massachusetts 


 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy